Bristol-Myers Squibb Stock News

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies. The post Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails appeared first on Investor's Business Daily.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Evidence Data at AHA 2024.

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It reported revenue of $11.9 billion and adjusted earnings of $1.80 per share, compared to the consensus estimates of $11.3 billion and $1.49, respectively.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Upcoming Investor Conferences.

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors' attention was on technology stocks. But that means you may have overlooked two biopharmaceutical companies that delivered solid earnings reports.

24/7 Wall St. Insights The seemingly endless political season is almost over.

24/7 Wall St. Insights The long AI-driven rally has many tech stocks overvalued.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #COBENFY--BMS Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ in Adults with Schizophrenia at Psych Congress 2024.